Compare HNRG & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNRG | SANA |
|---|---|---|
| Founded | 1949 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.2M | 793.1M |
| IPO Year | 1995 | 2021 |
| Metric | HNRG | SANA |
|---|---|---|
| Price | $15.24 | $3.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $25.38 | $7.80 |
| AVG Volume (30 Days) | 703.6K | ★ 3.0M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.78 | 17.24 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $469,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.09 | N/A |
| 52 Week Low | $14.68 | $2.61 |
| 52 Week High | $24.70 | $6.55 |
| Indicator | HNRG | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 39.76 | 42.92 |
| Support Level | $15.22 | $3.03 |
| Resistance Level | $20.08 | $3.41 |
| Average True Range (ATR) | 0.78 | 0.23 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 0.46 | 12.50 |
Hallador Energy Co is a vertically integrated, independent power producer (IPP) and fuel company with operations in Indiana. The Company operates across multiple stages of the energy value chain, from accredited capacity and energy to coal. The Company's electric operations are located within the Midcontinent Independent System Operator's (MISO) footprint. The company's business is organized based on the services and products it provide in two segments: (i) Electric Operations and (ii) Coal Operations.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.